Last updated date
ABOUT THIS STUDY
The purpose of this study is to collect effectiveness and safety information of fesoterodine
related to their appropriate use in daily practice.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Overactive Bladder (OAB)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
20 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Patients prescribed fesoterodine (Toviaz).
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- There are no exclustion criteria
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Overactive Bladder (OAB)Drug Use Investigation for Toviaz
NCT01936870
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Overactive Bladder (OAB)Detrol LA In Men With Overactive Bladder.
NCT00282932
- Anaheim, California
- La Mesa, California
- Aurora, Colorado
- Iowa City, Iowa
- Shreveport, Louisiana
- Watertown, Massachusetts
- Westampton, New Jersey
- New York, New York
- Cincinnati, Ohio
- State College, Pennsylvania
- Houston, Texas
- Calgary, Alberta
- Surrey, British Columbia
- Victoria, British Columbia
- Kingston, Ontario
- London, Ontario
- Oakville, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Pointe-Claire, Quebec
- Aalborg,
- Herlev,
- Nykobing Falster,
- Berlin,
- Duisburg,
- Frankfurt,
- Muelheim A.d. Ruhr,
- Muenchen,
- Muenchen,
- Rosenheim,
- Starnberg,
- Latina,
- Padova,
- Bucheon-si, Gyunggi-do
- Busan,
- Seoul,
- Seoul,
- Guadalajara, Jalisco
- Zapopan, Jalisco
- Tlalpan, México DF
- Durango,
- Durango,
- Bodø,
- Moelv,
- Bratislava,
- Kosice,
- Malacky,
- Martin,
- Skalica,
- Bloemfontein, Free State
- Bloemfontein, Free State
- Parktown, Gauteng Province
- Durban, Kwa Zulu Natal
- Pietermaritzburg, Kwa Zulu Natal
- Cape Town,
- A Coruna, A Coruña
- Palma de Mallorca, Islas Baleares
- Barcelona,
- Granada,
- Madrid,
- Madrid,
- Valencia,
- Boras,
- Huskvarna,
- Lund,
- Skovde,
- Hualien,
- Kaohsiung,
- Taipei,
- Taipei,
- Adana,
- Istanbul,
- Izmir,
- Sihhiye-Ankara,
- Bristol, Avon
- Crewe, Cheshire
- Taunton, Somerset
- London,
Male
40 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Drug Use Investigation for Toviaz | |||
| Official Title | Drug Use Investigation For Toviaz | |||
| Brief Summary | The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice. | |||
| Detailed Description | Not Provided | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Case-Only Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Probability Sample | |||
| Study Population | Patients prescribed fesoterodine (Toviaz) by investigators involved in protocol A0221096. | |||
| Condition | Overactive Bladder (OAB) | |||
| Intervention | Drug: Fesoterodine (Toviaz)
Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment. | |||
| Study Groups/Cohorts | Fesoterodine (Toviaz)
Intervention: Drug: Fesoterodine (Toviaz) | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 2521 | |||
| Original Estimated Enrollment | 2000 | |||
| Actual Study Completion Date | May 2016 | |||
| Actual Primary Completion Date | May 2016 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 20 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT01936870 | |||
| Other Study ID Numbers | A0221096 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2017 | |||